TY - JOUR T1 - Preliminary study on the pathogenesis of anal fistula JF - medRxiv DO - 10.1101/2021.04.15.21254769 SP - 2021.04.15.21254769 AU - Jingyi Zhu AU - Qingming Wang AU - Zubing Mei Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/22/2021.04.15.21254769.abstract N2 - BACKGROUND Anal gland infection is one of the main pathogenic factors of anal fistula. The anal gland is mainly consist of columnar epithelial cells and goblet cells. Goblet cells could secrete mucins which maintain the surface mucous gel layer of intestine to prevent columnar epithelial cells from the direct acting of bacteria. The absence or diminished secretion of goblet cells could lead to the exposure of columnar epithelial cells to bacteria. In recent years, studies have found that most of the microorganisms in perianal abscess and anal fistula are intestinal bacteria. So, it can be considered that the occurrence and development of anal fistula is closely related to gut microbiota. However, the molecular mechanism of gut microbiota acting on the epithelial cells of anal gland leading to the occurrence and development of anal fistula has not been explored.METHODS Anal fistula tissues were collected from 30 patients, and HE staining was employed to observe pathological changes of anal gland. Stool specimens were collected from normal group (14 normal subjects), preoperative group (21 subjects before surgery) and postoperative group (16 subjects after surgery). High-throughput 16S rRNA gene sequencing was performed to explore differences among different groups.RESULTS It was found by HE staining that normal anal gland is composed of a large number of columnar epithelial cells as well as goblet cells, while the anal gland of patients with anal fistula is seriously lack of goblet cells. In the normal ones, a large number of vacuoles formed by the dye dissolution of mucin particles can be seen at the top of the goblet cells, and a large amount of mucin secretion can be seen in the center of the anal gland. The results of high-throughput 16S rRNA gene sequencing showed that there were significant statistical differences in species richness, species evenness and species composition between the preoperation group and the normal group (P1 =0.00004), and between the preoperative group and the postoperative group (P2 =0.00003). It also showed that PWY-6471 metabolic pathway was the most significant difference between the preoperative group and the postoperative group (P=0.0033).CONCLUSIONS The occurrence of anal fistula may be related to the abnormal permeability of mucus layer and the change of intestinal flora composition. The absence or diminished secretion of goblet cells may cause exception of the permeability of mucus layer which makes the columnar epithelial cells of anal gland exposed to the direct contact of peptidoglycan. The metabolite of pathogenic microorganisms could activate the signal pathway (i.g. NLR/NF-κB) which leading to the overexpression of inflammatory factors and cause anal fistula.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialEthical approval was obtained from the China Ethics Committee of Registering Clinical Trials (Approval No. ChiECRCT20200448).Funding StatementThis work was supported by the Science and Technology Commission of Shanghai Municipality (grant no. 19401933900) (to Q.W.). This sponsor did not have any involvement in the study design; collection, analysis, or interpretation of data; writing of the report; or the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the China Ethics Committee of Registering Clinical Trials (Approval No. ChiECRCT20200448).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. ER -